Bedinvetmab
| Monoclonal antibody | |
|---|---|
| Type | Whole antibody |
| Target | Nerve growth factor (NGF) |
| Clinical data | |
| Trade names | Librela |
| AHFS/Drugs.com | Veterinary Use |
| License data |
|
| Routes of administration | Subcutaneous |
| ATCvet code | |
| Legal status | |
| Legal status | |
| Identifiers | |
| CAS Number | |
| UNII | |
Bedinvetmab, sold under the brand name Librela, is a canine monoclonal antibody used for the control of pain associated with osteoarthritis in dogs. Librela is sponsored by Zoetis.
The most common side effects include elevated blood urea nitrogen (an indicator of kidney function), urinary tract infection, bacterial skin infection, skin irritation, rash or pain at injection site, vomiting, and weight loss. The FDA issued a warning in December 2024 stating the drug may cause serious side effects, primarily neurological in nature, such as: ataxia, seizures, paresis, recumbency, urinary incontinence, polyuria, and polydipsia.
Bedinvetmab was approved for medical use in the European Union in November 2020, and in the United States in May 2023. Bedinvetmab is the first monoclonal antibody approved in the United States for controlling osteoarthritis pain in dogs.